What IV levothyroxine dose corresponds to an oral dose of 112 µg (micrograms) for IV push administration?

IV Levothyroxine Conversion from 112 mcg Oral Dose

For a patient taking levothyroxine 112 mcg orally, administer 78 mcg (or approximately 75-80 mcg) intravenously, which represents 70% of the oral dose.

Conversion Rationale

The conversion is based on the bioavailability difference between oral and IV routes. Approximately 70% of an orally administered levothyroxine dose is absorbed from the gastrointestinal tract 1. Since IV administration bypasses GI absorption entirely and delivers 100% bioavailability, patients unable to take oral medication should receive 70% or less of their usual oral dose when switched to IV 1.

Calculation

• Oral dose: 112 mcg
• IV dose: 112 mcg × 0.70 = 78.4 mcg
• Practical dosing: 75-80 mcg IV (round to available vial strengths)

Clinical Context and Monitoring

Indications for IV Administration

IV levothyroxine is appropriate when 2, 3:

• Insufficient GI absorption due to gastrointestinal pathology
• Partial or total loss of consciousness
• Sedation in intensive care settings
• Shock states
• Myxedema coma (though this requires loading doses, not simple conversion)

Important Caveats

Start with conservative dosing (≤70% of oral dose) rather than the full calculated amount, particularly in:

• Elderly patients
• Patients with underlying cardiovascular disease
• Those with occult cardiac conditions
• Patients who may have been non-compliant with oral therapy (potentially receiving less than prescribed)

The guideline specifically states patients should receive "70% or less" of their usual dose 1, emphasizing that 70% is the maximum, not a target.

Duration and Transition

• Continue IV therapy for 3-10 days until the patient can resume oral intake 2
• Ensure normal GI function is restored before transitioning back to oral therapy
• When resuming oral medication, return to the original oral dose (112 mcg in this case)

Monitoring Parameters

Once IV therapy is initiated:

• Monitor for cardiac symptoms (tachycardia, arrhythmias, angina)
• Check TSH and free T4 levels at 4-8 weeks after any route change 1
• In patients with cardiovascular disease, monitor closely for precipitating cardiac events
• If cardiac symptoms develop, reduce or withhold the dose temporarily

Stability Considerations

If preparing IV levothyroxine solutions 4, 5:

• Solutions at 0.4 mcg/mL in 0.9% NaCl are stable for 24 hours at room temperature when protected from light 5
• More concentrated solutions (2.0 mcg/mL) are stable for at least 12 hours if protected from light 4
• Store at room temperature (25°C)
• Protect from light for optimal stability

Common Pitfalls to Avoid

1. Do not give the full oral dose IV - this would result in approximately 40% overdosing due to complete bioavailability
2. Do not use IV conversion formulas for myxedema coma - that condition requires specific loading doses (typically 300-500 mcg), not simple conversion 6
3. Avoid abrupt dose changes in cardiac patients - use the lower end of the conversion range (closer to 60-70% rather than 70%)
4. Do not forget to adjust back to oral dosing - when resuming oral therapy, return to the pre-IV oral dose, not 70% higher